益生菌:作为对乙酰氨基酚诱导的肝毒性的潜在治疗选择不断发展。

Probiotics: Evolving as a Potential Therapeutic Option against Acetaminophen-Induced Hepatotoxicity.

作者信息

Dewanjee Saikat, Dua Tarun K, Paul Paramita, Dey Abhijit, Vallamkondu Jayalakshmi, Samanta Sonalinandini, Kandimalla Ramesh, De Feo Vincenzo

机构信息

Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India.

Department of Pharmaceutical Technology, University of North Bengal, Raja Rammohunpur 734013, India.

出版信息

Biomedicines. 2022 Jun 24;10(7):1498. doi: 10.3390/biomedicines10071498.

Abstract

Acetaminophen (APAP) is the most common prescription medicine around the world for the treatment of pain and fever and is considered to be a safe drug at its therapeutic dose. However, a single overdose or frequent use of APAP can cause severe acute liver injury. APAP hepatotoxicity is a prevalent cause of acute liver disease around the world and the lack of suitable treatment makes it a serious problem. In recent years, there has been a surge in interest in using probiotics and probiotic-derived products, known as postbiotics, as health and disease negotiators. A growing body of evidence revealed that they can be equally effective against APAP hepatotoxicity. Different probiotic bacteria were found to be pre-clinically effective against APAP hepatotoxicity. Different postbiotics have also shown exciting results in preclinical models of APAP hepatotoxicity. This review summarized the protective roles and mechanisms of the different probiotic bacteria and postbiotics against APAP hepatotoxicity, with critical discussion. A brief discussion on potential novel probiotics and postbiotics for oxidative liver injury was also included. This review was written in an attempt to pique the interest of researchers in developing a safe therapeutic option against oxidative liver damage using probiotics and/or postbiotics as dietary supplements.

摘要

对乙酰氨基酚(APAP)是全球治疗疼痛和发热最常用的处方药,在治疗剂量下被认为是一种安全的药物。然而,单次过量服用或频繁使用APAP会导致严重的急性肝损伤。APAP肝毒性是全球急性肝病的一个普遍原因,而缺乏合适的治疗方法使其成为一个严重的问题。近年来,人们对使用益生菌和益生菌衍生产品(即后生元)作为健康和疾病调节因子的兴趣激增。越来越多的证据表明,它们对APAP肝毒性同样有效。研究发现,不同的益生菌在临床前对APAP肝毒性有效。不同的后生元在APAP肝毒性的临床前模型中也显示出令人兴奋的结果。本综述总结了不同益生菌和后生元对APAP肝毒性的保护作用和机制,并进行了批判性讨论。还简要讨论了针对氧化性肝损伤的潜在新型益生菌和后生元。撰写本综述旨在激发研究人员的兴趣,开发一种使用益生菌和/或后生元作为膳食补充剂来对抗氧化性肝损伤的安全治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f42/9312935/ae309b922167/biomedicines-10-01498-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索